pharmaphorum

OCTOBER 5, 2022

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. billion deal in 2018. The aim will be to identify promising candidates in areas of “unmet patient need.”

RNA 105

RNA Genetics Dermatology Antibody 105

XTalks

JUNE 20, 2022

Small interfering RNAs (siRNAs) are a promising class of therapeutic modalities that involve a double-stranded RNA molecule (20 to 25 bp long) which can target and cease the translation of a disease-related mRNA. 1 (transforming growth factor beta1) and the enzyme COX-2 (cyclooxygenase-2) is strongly linked with SCC development.

RNA 96

RNA Clinical Trials Clinical Trials Dermatology 96

XTalks

AUGUST 2, 2023

2) Veklury (remdesivir) Veklury, approved by the FDA in 2020, is a SARS-CoV-2 nucleotide analog RNA polymerase inhibitor designed for the treatment of COVID-19. It also has a significant presence in consumer health sectors such as dermatology, nutritionals and allergy. Veklury generated a revenue of $3.91 billion in 2022.

Sales 98

Sales Manufacturing FDA Approval Life Science 98